Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

EADO 2018 /
The emerging era of no-completion lymph node dissection

6th - 9th Nov 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 20.11.18
Views: 422

Dr Daniel Coit - Memorial Sloan Kettering Cancer Centre, New York, USA

Dr Daniel Coit speaks with ecancer at the EADO 2018 congress in Barcelona about the emergence of no-completion lymph node dissection for patients with a positive sentinel node.

Dr Coit explains that recently two prospective randomised trials have concluded that nearly all the important clinical end points were similar whether the patient had a completion lymph node dissection or not.

He believes the results to be practice changing but that change of practice could be difficult due to the general conservative nature of practices in regards to change.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation